Dr Belinda Quinn appointed as Chief Executive of the Precision Medicine Catapult

Quinn has been Chief Medical Officer of the organisation for the past six months

The Precision Medicine Catapult, the UK's innovation centre for precision (or personalised) medicine, has appointed Dr Belinda Quinn as Chief Executive.

Quinn has been Chief Clinical Officer of the Precision Medicine Catapult for the past six months, formulating and landscaping Precision Medicine opportunities across the UK. She has played a pivotal leadership role in mobilising the seven Centres of Excellence integral to the success of the Precision Medicine Catapult.

Quinn trained as a doctor specialising in neurology before diversifying into IT and clinical leadership roles. She has held executive roles across the public and private sector including big pharma, global management consulting, the NHS, data and regulatory in the UK, Australia and the Middle East.

You may also like

Regulatory

CGT Catapult analyses manufacturing and skills in cell and gene therapy

New data has shown cell and gene therapy manufacturing facilities are rapidly becoming operational reflecting job expansion in the sector
Media

British cell and gene therapy accelerator releases annual report

The CGT Catapult has worked on more than 110 projects addressing industry challenges
Research & Development

CGT Catapult brings SMEs together

Fujifilm Diosynth, Eversheds Sutherland, Mathys & Squire and Stifel gather at CGT Catapult’s first UK Advanced Therapy Medicinal Products Investor Day
Research & Development

TCR2 Therapeutics and CGT Catapult join forces at UK Bioscience park

TCR<sup>2</sup> is the first US company to have a global development base at the Stevenage site, working with CGT Catapult to further its T cell therapies
Research & Development

CGT Catapult engages academic hubs to support translation of research

Dissemination of expertise and knowledge in commercial translation aims to speed up the adoption of technologies emerging from UK research
Research & Development

REPROCELL join Medicines Discovery Catapult’s R&D network to accelerate drug development

The collaboration is part of Medicines Discovery Catapult’s virtual R&D network, which aims to support UK SMEs develop and execute their drug discovery projects with industrial rigour
Regulatory

Surge in cell and gene therapy trials highlight the UK’s leading position as developmental hub in this innovative industry

Global industry shows confidence in cell and gene therapies and in UK’s ability to deliver these life-changing products
Subscribe now